Research
Hormonal
Incidental exposure to incretin-based medications during early pregnancy is becoming more likely.
Clinicians should be aware of the risks of medication exposure in unplanned pregnancies.
StrongSupportsmedium confidence
With unplanned pregnancies remaining common, incidental exposure during early pregnancy is becoming more likely.
Why this rating
The claim is based on observed trends in pregnancy occurrences.
Source
Preconception use of GLP-1 and GLP-1/GIP receptor agonists for obesity treatment
Andrijana Koceva et al. · Best Practice & Research Clinical Endocrinology & Metabolism · 2025
DOI 10.1016/j.beem.2025.102038
reviewCited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →